1. Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea;
2. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea;
J Cancer. 2016 Jan 29;7(3):289-96. doi: 10.7150/jca.13432. eCollection 2016.
To measure the prognostic value of the lymphocyte-monocyte ratio (LMR) in patients with epithelial ovarian cancer (EOC).
We retrospectively examined the LMR as a prognosticator in a cohort of 234 patients with EOC who underwent surgical resection. Patients were categorized into two different groups based on the LMR (LMR-low and LMR-high) using cut-off values determined by receiver operating characteristic (ROC) curve analysis. The objective of the study was to assess the effect of the LMR on progression-free survival (PFS) and overall survival (OS), and to validate the LMR as an independent predictor of survival.
Using the data collected from the whole cohort, the optimized LMR cut-off value selected on the ROC curve was 2.07 for both PFS and OS. The LMR-low and LMR-high groups included 48 (20.5%) and 186 patients (79.5%), respectively. The 5-year PFS rates in the LMR-low and LMR-high groups were 40.0 and 62.5% (P < 0.0001), respectively, and the 5-year OS rates in these two groups were 42.2 and 67.2% (P < 0.0001), respectively. On multivariate analysis, we identified age, International Federation of Gynecology and Obstetrics (FIGO) stage, and cancer antigen 125 levels to be the strongest valuable prognostic factors affecting PFS (P = 0.0421, P = 0.0012, and P = 0.0313, respectively) and age, FIGO stage, and the LMR as the most valuable prognostic factors predicting OS (P = 0.0064, P = 0.0029, and P = 0.0293, respectively). Conclusion : The LMR is an independent prognostic factor affecting the survival of patients with EOC.
测量淋巴细胞-单核细胞比值(LMR)在卵巢上皮癌(EOC)患者中的预后价值。
我们回顾性地检查了 234 例接受手术切除的 EOC 患者队列中 LMR 作为预后标志物的情况。根据接受者操作特征(ROC)曲线分析确定的截断值,将患者分为两个不同的 LMR 组(LMR-低和 LMR-高)。研究的目的是评估 LMR 对无进展生存期(PFS)和总生存期(OS)的影响,并验证 LMR 作为生存的独立预测因子。
使用从整个队列中收集的数据,ROC 曲线选择的最佳 LMR 截断值在 PFS 和 OS 中均为 2.07。LMR-低和 LMR-高组分别包括 48(20.5%)和 186 例患者(79.5%)。LMR-低和 LMR-高组的 5 年 PFS 率分别为 40.0%和 62.5%(P<0.0001),两组的 5 年 OS 率分别为 42.2%和 67.2%(P<0.0001)。多变量分析显示,年龄、国际妇产科联合会(FIGO)分期和癌症抗原 125 水平是影响 PFS 的最强有价值的预后因素(P=0.0421、P=0.0012 和 P=0.0313),年龄、FIGO 分期和 LMR 是预测 OS 的最有价值的预后因素(P=0.0064、P=0.0029 和 P=0.0293)。结论:LMR 是影响 EOC 患者生存的独立预后因素。